- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Patent holdings for IPC class A61P 29/00
Total number of patents in this class: 20905
10-year publication summary
|
805
|
755
|
1158
|
1398
|
1518
|
1606
|
1725
|
1672
|
1447
|
770
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7930 |
215 |
| Boehringer Ingelheim International GmbH | 4656 |
183 |
| Bristol-myers Squibb Company | 4878 |
174 |
| Janssen Pharmaceutica N.V. | 3395 |
149 |
| Takeda Pharmaceutical Company Limited | 2714 |
137 |
| Novartis AG | 10847 |
135 |
| The Regents of the University of California | 19898 |
106 |
| AstraZeneca AB | 2920 |
103 |
| Allergan, Inc. | 2349 |
102 |
| Genentech, Inc. | 3971 |
91 |
| Centre National de La Recherche Scientifique | 10421 |
90 |
| Daiichi Sankyo Company, Limited | 1863 |
90 |
| Hoffmann-La Roche Inc. | 3414 |
83 |
| Grünenthal GmbH | 572 |
83 |
| Merck Patent GmbH | 5830 |
80 |
| Glaxo Group Limited | 4080 |
79 |
| Amgen Inc. | 4072 |
77 |
| Vertex Pharmaceuticals Incorporated | 1599 |
74 |
| Gilead Sciences, Inc. | 2037 |
74 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 823 |
67 |
| Other owners | 18713 |